Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme

Liver International

Volumn 37, Issue 9, 2017, Pages 1314-1324

  Hézode, Christophe ^a   Lebray, Pascal ^b   De Ledinghen, Victor ^c   Zoulim, Fabien ^d   Di Martino, Vincent ^e   Boyer, Nathalie ^f   Larrey, Dominique ^g   Botta Fridlund, Danielle ^h   Silvain, Christine ⁱ   Fontaine, Hélène ^j   D'Alteroche, Louis ^k   Leroy, Vincent ^l   Bourliere, Marc ^m   Hubert Fouchard, Isabelle ⁿ   Guyader, Dominique ^o   Rosa, Isabelle ^p   Nguyen Khac, Eric ^q   Fedchuk, Larysa ^r   Akremi, Raoudha ^r   Bennai, Yacia ^r   Filipovics, Anne ^r   Zhao, Yue ^r   Bronowicki, Jean Pierre ^s   more..

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d CROIX ROUSSE HOSPITAL   (France)

^e UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^f BEAUJON HOSPITAL   (France)

^g HÔPITAL SAINT ELOI   (France)

^h AIX MARSEILLE UNIVERSITY   (France)

ⁱ POITIERS UNIVERSITY HOSPITAL   (France)

^j Pasteur Institute U1223 ^*  (France)

^k SERVICE DE DERMATOLOGIE   (France)

^l GRENOBLE UNIVERSITY HOSPITAL   (France)

^m HÔPITAL SAINT JOSEPH   (France)

ⁿ ANGERS UNIVERSITY HOSPITAL   (France)

^o RENNES UNIVERSITY HOSPITAL   (France)

^p CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^q AMIENS UNIVERSITY HOSPITAL   (France)

^r BRISTOL MYERS SQUIBB   (United States)

^s UNIVERSITÉ DE LORRAINE   (France)

more..

Author keywords

compassionate use; daclatasvir; genotype 3; hepatitis C; real world data; sofosbuvir

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; DACLATASVIR; EFAVIRENZ; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; BRAIN HEMORRHAGE; CHILD PUGH SCORE; CHRONIC HEPATITIS C; DECOMPENSATED LIVER CIRRHOSIS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HEPATOBILIARY DISEASE; HEPATORENAL SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFESTATION; INTENTION TO TREAT ANALYSIS; INTESTINE OBSTRUCTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; LUNG EMBOLISM; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MIXED INFECTION; MODEL FOR END STAGE LIVER DISEASE SCORE; MULTIPLE ORGAN FAILURE; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; NUTRITIONAL DISORDER; PERITONITIS; PNEUMONIA; RECOMMENDED DRUG DOSE; RECURRENT INFECTION; RESPIRATORY DISTRESS; SEPTIC SHOCK; SIDE EFFECT; SKIN ALLERGY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT INTERRUPTION; TREATMENT RESPONSE; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMPLICATION; FRANCE; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; RECURRENT DISEASE; SUSTAINED VIROLOGIC RESPONSE; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE;

EID: 85014667661     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13383     Document Type: Article

References (16)

1. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77-87.
2. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut. 2006;55:123-130.
3. Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat. 2011;18:e516-e522.
4. Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009;51:655-666.
5. McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med. 2014;174:204-212.
6. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:96-100.
7. Sofia MJ, Bao D, Chang W, et al. Discovery of a β-d-2’-deoxy-2’-α-fluoro-2’-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem. 2010;53:7202-7218.
8. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology. 2015;61:1127-1135.
9. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org [Accessed 13 January 2017].
10. Association Français pour l'Etude du Foie. Recommandations AFEF sur la prise en charge des hépatites virales C (Février 2016). http://www.afef.asso.fr/ckfinder/userfiles/files/recommandations-textes-officiels/Recoavril2016.pdf [Accessed 13 January 2017].
11. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153-194.
12. Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. 2016;63:1430-1441.
13. Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virologic response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65:1861-1870.
14. Ioannou GN, Beste LA, Chang MF, et al. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology. 2016;151:457-471e5.
15. Feld JJ, Maan R, Zeuzem S, et al. Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: results of the HCV-TARGET Study. Clin Infect Dis. 2016;63:776-783.
16. Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224-1231.